Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like?
The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like?
The House of Representatives narrowly passed a budget...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
The Plot Thickens in Drug Pricing Drama
Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama
Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
Researchers examined the association between a prescription digital therapeutic designed to deliver cognitive behavioral therapy to patients with insomnia and the incidence of acute cardiovascular events requiring hospitalization.
Researchers examined the association between a prescription digital therapeutic designed to deliver cognitive behavioral therapy to patients with insomnia and the incidence of acute cardiovascular events requiring hospitalization.
Norm Smith, principal payer market research consultant, predicts how payment and patient access strategies may shift once COVID-19 vaccines hit the commercial market and coverage requirements set during the public health emergency expire.
Norm Smith, principal payer market research consultant, predicts how payment and patient access strategies may shift once COVID-19 vaccines hit the commercial market and coverage requirements set during the public health emergency expire.
Researchers suggest that an extended interval dosing regimen could be effective in preventing a decline in immunoglobulin levels whilst maintaining disease stability for patients with multiple sclerosis (MS) on ocrelizumab.
Researchers suggest that an extended interval dosing regimen could be effective in preventing a decline in immunoglobulin levels whilst maintaining disease stability for patients with multiple sclerosis (MS) on ocrelizumab.
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers.
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers.